L. McDermott

发表

Comparative In Vitro Activities of Daptomycin and Vancomycin against Resistant Gram-Positive Pathogens

D. Snydman, J. Boyce, N. Jacobus, 2000, Antimicrobial Agents and Chemotherapy.

Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).

D. Snydman, J. Rosenblatt, V. Yu, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients.

D. Snydman, L. Mcdermott, José A. Martínez, 2002, The Journal of antimicrobial chemotherapy.

Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial.

D. Snydman, V. Yu, L. Mcdermott, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Multicenter Study of In Vitro Susceptibility of theBacteroides fragilis Group, 1995 to 1996, with Comparison of Resistance Trends from 1990 to 1996

D. Snydman, S. Gorbach, S. Jenkins, 1999, Antimicrobial Agents and Chemotherapy.

Comparison of the Semisolid Agar Antifungal Susceptibility Test with the NCCLS M38-P Broth Microdilution Test for Screening of Filamentous Fungi

S. Hadley, Ç. Kuzucu, Barbara Rapino, 2004, Journal of Clinical Microbiology.

Selective method for identification and quantification of Bifidobacterium animalis subspecies lactis BB‐12 (BB‐12) from the gastrointestinal tract of healthy volunteers ingesting a combination probiotic of BB‐12 and Lactobacillus rhamnosus GG

D. Snydman, B. Goldin, A. Kane, 2017, Journal of applied microbiology.

National survey on the susceptibility of Bacteroides Fragilis Group: report and analysis of trends for 1997-2000.

D. Snydman, R. Venezia, E. Goldstein, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

In Vitro Activities of Tigecycline against the Bacteroides fragilis Group

D. Snydman, R. Ruthazer, N. Jacobus, 2004, Antimicrobial Agents and Chemotherapy.

Evaluation of In Vitro Interaction of Daptomycin with Gentamicin or Beta-lactam Antibiotics Against taphylococcus aureus and Enterococci by FIC Index and Timed-Kill Curves

D. Snydman, N. Jacobus, L. McDermott, 2005, Journal of chemotherapy.

Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?

F. Marty, D. Kontoyiannis, David A. Oxman, 2010, The Journal of antimicrobial chemotherapy.

In Vitro Activities of Newer Quinolones against Bacteroides Group Organisms

D. Snydman, R. Venezia, E. Goldstein, 2002, Antimicrobial Agents and Chemotherapy.

Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010-2012 with comparison to 2008-2009.

D. Snydman, Robin Patel, E. Goldstein, 2017, Anaerobe.

U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016

D. Snydman, B. A. Forbes, D. Gerding, 2019, Antimicrobial Agents and Chemotherapy.

Comparative In Vitro Activities of Clinafloxacin and Trovafloxacin against 1,000 Isolates of Bacteroides fragilisGroup: Effect of the Medium on Test Results

D. Snydman, N. Jacobus, S. Supran, 2000, Antimicrobial Agents and Chemotherapy.

A repeat offender: Recurrent extraintestinal Clostridium difficile infection following fecal microbiota transplantation.

D. Snydman, S. Walk, L. Mcdermott, 2018, Anaerobe.

Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009.

D. Snydman, J. Rosenblatt, R. Venezia, 2011, Anaerobe.

Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin

D. Snydman, S. Walk, L. Mcdermott, 2018, The Journal of antimicrobial chemotherapy.

In Vitro Evaluation of the Activity of Imipenem-Relebactam against 451 Recent Clinical Isolates of Bacteroides Group and Related Species

D. Snydman, N. Jacobus, L. McDermott, 2016, Antimicrobial Agents and Chemotherapy.

National Survey on the Susceptibility of Bacteroides fragilis Group: Report and Analysis of Trends in the United States from 1997 to 2004

N. V. Jacobus, R. Ruthazer, D. Snydman, 2007, Antimicrobial Agents and Chemotherapy.

Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates

D. Snydman, T. Grossman, N. Jacobus, 2018, Antimicrobial Agents and Chemotherapy.

Effect of pH on in vitro antimicrobial susceptibility of the Bacteroides fragilis group

D. Snydman, M. Falagas, L. McDermott, 1997, Antimicrobial agents and chemotherapy.

In Vitro Susceptibilities of the Bacteroides fragilis Group Species: Change in Isolation Rates Significantly Affects Overall Susceptibility Data

D. Snydman, R. Venezia, E. Goldstein, 2002 .

Correlation of various in vitro testing methods with clinical outcomes in patients with Bacteroides fragilis group infections treated with cefoxitin: a retrospective analysis

D. Snydman, G. Cuchural, M. Gill, 1992, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of Ceftaroline against a Broad Spectrum of Recent Clinical Anaerobic Isolates

D. Snydman, N. Jacobus, L. McDermott, 2010, Antimicrobial Agents and Chemotherapy.

Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.

D. Snydman, V. Yu, S. Gorbach, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Activity of Ceftolozane-Tazobactam against a Broad Spectrum of Recent Clinical Anaerobic Isolates

D. Snydman, N. Jacobus, L. McDermott, 2013, Antimicrobial Agents and Chemotherapy.

a Broad Spectrum of Recent Clinical Activity of Ceftolozane-Tazobactam against

D. Snydman, L. McDermott, 2014 .

Emergence of fluoroquinolone resistance among Bacteroides species.

D. Snydman, R. Venezia, E. Goldstein, 2003, The Journal of antimicrobial chemotherapy.

Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989.

D. Snydman, S. Finegold, J. Rihs, 1992, Clinical therapeutics.

U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin

D. Snydman, B. A. Forbes, D. Gerding, 2015, Antimicrobial Agents and Chemotherapy.

Activity of a Novel Cyclic Lipopeptide, CB-183,315, against Resistant Clostridium difficile and Other Gram-Positive Aerobic and Anaerobic Intestinal Pathogens

D. Snydman, N. Jacobus, L. McDermott, 2012, Antimicrobial Agents and Chemotherapy.

In Vitro Activities of Doripenem, a New Broad-Spectrum Carbapenem, against Recently Collected Clinical Anaerobic Isolates, with Emphasis on the Bacteroides fragilis Group

D. Snydman, N. Jacobus, L. McDermott, 2008, Antimicrobial Agents and Chemotherapy.

Epidemiologic Trends in Clostridium difficile Isolate Ribotypes in United States from 2010 to 2014

D. Snydman, B. A. Forbes, Robin Patel, 2017, Open Forum Infectious Diseases.

Effect of Lactobacillus rhamnosus GG Administration on Vancomycin-Resistant Enterococcus Colonization in Adults with Comorbidities

D. Snydman, B. Goldin, S. Doron, 2015, Antimicrobial Agents and Chemotherapy.

Epidemiologic trends in Clostridioides difficile isolate ribotypes in United States from 2011 to 2016.

D. Snydman, B. A. Forbes, D. Gerding, 2020, Anaerobe.

ANALYSIS OF THE IN VITRO ACTIVITY OF TROVAFLOXACIN (CP‐99,219) AGAINST BACTEROIDES SPECIES

D. Snydman, L. McDermott, 1996 .

In Vitro Evaluation of the Activity of Aztreonam-Avibactam against 341 Recent Clinical Isolates of Anaerobes

D. Snydman, L. Mcdermott, L. McDermott, 2021, Microbiology spectrum.

Differences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients

D. Snydman, D. Gerding, D. Hecht, 2016, Antimicrobial Agents and Chemotherapy.

A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020–2021

L. Gluck, K. Garey, L. McDermott, 2023, Antimicrobial Agents and Chemotherapy.

In Vitro Evaluation of the Activity of Imipenem-Relebactam against 451 Recent Clinical Isolates of Bacteroides Group and Related Species

D. Snydman, N. Jacobus, L. McDermott, 2016, Antimicrobial Agents and Chemotherapy.